Literature DB >> 35155064

Vestibular Schwannoma Tumor Size and Growth Rate Predict Response with Gamma Knife Stereotactic Radiosurgery.

Daniel E Killeen1, Anthony M Tolisano2, Brandon Isaacson1, J Walter Kutz1, Samuel Barnett3, Zabi Wardak4, Jacob B Hunter1.   

Abstract

Objective  The aim of this study is to determine if pretreatment growth of sporadic vestibular schwannomas (VS) predicts postradiosurgery response. Methods  This study was a retrospective chart review at a tertiary referral center of patients with VS that had at least two pretreatment magnetic resonance imaging (MRI) studies at least 6 months apart and underwent Gamma Knife radiosurgery with a minimum of 14 months postradiosurgery imaging surveillance. Tumor linear measurements and volumetric segmentation were assessed before and after radiosurgery. The main outcome measure was persistent enlargement following radiosurgery, defined as 2 mm enlargement in greatest axial diameter or 20% enlargement in volume without size regression. Results  Thirty-five patients met the inclusion criteria. Patients were observed for median pre- and posttreatment intervals of 29.5 and 40.6 months, respectively. Median dose to the tumor margin was 13 Gy. Postradiosurgery enlargement occurred in six (17.1%) and nine (25.7%) patients based on linear and volumetric enlargement definitions, respectively. Pseudoprogression-defined as tumor enlargement-followed by linear or volumetric regression that occurred in 34.3% of tumors, reaching a maximum size at a median time of 6.3 months (3.3-8.4) postradiosurgery. When controlling for age, gender, and radiation dose, preradiosurgery tumor volume less than 0.3 cm 3 (odds ratio [OR]: 59.7, p  = 0.012) and preradiosurgery tumor diameter growth rate greater than or equal to 2.5 mm/year (OR: 19.3, p  = 0.045) were associated with persistent postradiosurgery tumor enlargement. Conclusion  Smaller pretreatment tumor volume and greater linear tumor growth rates were associated with postradiosurgery tumor enlargement when controlling for age, gender, and radiation dose. Level of Evidence  This study indicates that the level of evidence is V. Thieme. All rights reserved.

Entities:  

Keywords:  Gamma Knife; radiation; radiosurgery; vestibular schwannoma; volumetric analysis

Year:  2020        PMID: 35155064      PMCID: PMC8824627          DOI: 10.1055/s-0040-1716677

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  23 in total

1.  Impact of pretreatment growth on Tumor control for vestibular schwannomas following gamma knife.

Authors:  Joseph Chang; Jonathan D Breshears; Annette M Molinaro; Penny K Sneed; Michael W McDermott; Philip V Theodosopoulos; Aaron D Tward
Journal:  Laryngoscope       Date:  2018-11-08       Impact factor: 3.325

Review 2.  Systematic review of quality of life in the management of vestibular schwannoma.

Authors:  Andrew Gauden; Philip Weir; Graeme Hawthorne; Andrew Kaye
Journal:  J Clin Neurosci       Date:  2011-10-19       Impact factor: 1.961

3.  Long term results of primary radiosurgery for vestibular schwannomas.

Authors:  Stephen Johnson; Hideyuki Kano; Andrew Faramand; Matthew Pease; Aya Nakamura; Mohab Hassib; David Spencer; Nathaniel Sisterson; Amir H Faraji; Yoshio Arai; Edward Monaco; Ajay Niranjan; John C Flickinger; L Dade Lunsford
Journal:  J Neurooncol       Date:  2019-09-18       Impact factor: 4.130

4.  Pretreatment growth rate as a predictor of tumor control following Gamma Knife radiosurgery for sporadic vestibular schwannoma.

Authors:  Alexander P Marston; Jeffrey T Jacob; Matthew L Carlson; Bruce E Pollock; Colin L W Driscoll; Michael J Link
Journal:  J Neurosurg       Date:  2016-11-25       Impact factor: 5.115

5.  Long-term safety and efficacy of stereotactic radiosurgery for vestibular schwannomas: evaluation of 440 patients more than 10 years after treatment with Gamma Knife surgery.

Authors:  Toshinori Hasegawa; Yoshihisa Kida; Takenori Kato; Hiroshi Iizuka; Shunichiro Kuramitsu; Takashi Yamamoto
Journal:  J Neurosurg       Date:  2012-11-09       Impact factor: 5.115

Review 6.  The hypoxic tumour microenvironment, patient selection and hypoxia-modifying treatments.

Authors:  I J Hoogsteen; H A M Marres; A J van der Kogel; J H A M Kaanders
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-04-12       Impact factor: 4.126

7.  Gamma knife radiosurgery for vestibular schwannomas: identification of predictors for continued tumor growth and the influence of documented tumor growth preceding radiation treatment.

Authors:  Ferdinand C A Timmer; Jef J S Mulder; Patrick E J Hanssens; J J van Overbeeke; Rogier T Donders; Cor W R J Cremers; Kees Graamans
Journal:  Laryngoscope       Date:  2011-08-16       Impact factor: 3.325

8.  Ten-Year Follow-up on Tumor Growth and Hearing in Patients Observed With an Intracanalicular Vestibular Schwannoma.

Authors:  Malene Kirchmann; Kirstine Karnov; Søren Hansen; Thomas Dethloff; Sven-Eric Stangerup; Per Caye-Thomasen
Journal:  Neurosurgery       Date:  2017-01-01       Impact factor: 4.654

9.  Pretreatment growth rate predicts radiation response in vestibular schwannomas.

Authors:  Nina N Niu; Andrzej Niemierko; Mykol Larvie; Hugh Curtin; Jay S Loeffler; Michael J McKenna; Helen A Shih
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-05-01       Impact factor: 7.038

10.  Identifying predictors of early growth response and adverse radiation effects of vestibular schwannomas to radiosurgery.

Authors:  Soroush Larjani; Eric Monsalves; Houman Pebdani; Boris Krischek; Fred Gentili; Michael Cusimano; Normand Laperriere; Caroline Hayhurst; Gelareh Zadeh
Journal:  PLoS One       Date:  2014-10-22       Impact factor: 3.240

View more
  1 in total

1.  Vestibular schwannoma associated with neurofibromatosis type 2: Clinical course following stereotactic radiosurgery.

Authors:  Junhyung Kim; Yukyeng Byeon; Sang Woo Song; Young Hyun Cho; Chang-Ki Hong; Seok Ho Hong; Jeong Hoon Kim; Do Heui Lee; Ji Eun Park; Ho Sung Kim; Young-Hoon Kim
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.